| Literature DB >> 23057008 |
Franz Rödel1, Benjamin Frey, Katrin Manda, Guido Hildebrandt, Stephanie Hehlgans, Ludwig Keilholz, M Heinrich Seegenschmiedt, Udo S Gaipl, Claus Rödel.
Abstract
Inflammatory diseases are the result of complex and pathologically unbalanced multicellular interactions. For decades, low-dose X-irradiation therapy (LD-RT) has been clinically documented to exert an anti-inflammatory effect on benign diseases and chronic degenerative disorders. By contrast, experimental studies to confirm the effectiveness and to reveal underlying cellular and molecular mechanisms are still at their early stages. During the last decade, however, the modulation of a multitude of immunological processes by LD-RT has been explored in vitro and in vivo. These include leukocyte/endothelial cell adhesion, adhesion molecule and cytokine/chemokine expression, apoptosis induction, and mononuclear/polymorphonuclear cell metabolism and activity. Interestingly, these mechanisms display comparable dose dependences and dose-effect relationships with a maximum effect in the range between 0.3 and 0.7 Gy, already empirically identified to be most effective in the clinical routine. This review summarizes data and models exploring the mechanisms underlying the immunomodulatory properties of LD-RT that may serve as a prerequisite for further systematic analyses to optimize low-dose irradiation procedures in future clinical practice.Entities:
Keywords: discontinuous dose dependency; immune modulation; inflammation; low-dose radiation therapy
Year: 2012 PMID: 23057008 PMCID: PMC3457026 DOI: 10.3389/fonc.2012.00120
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Preclinical models and clinical/experimental parameters for the analyses of the anti-inflammatory effects of low-dose irradiation.
| Experimental model ( | SD/TD | Time of irradiation | Clinical/biological effects | References |
|---|---|---|---|---|
| SD 1.0 Gy | Different | ↓ Inflammatory symptoms, ↓ pain ≈ degenerative changes | von Pannewitz ( | |
| SD 1.5 Gy | 1× Week immediately | ↓ Joint swelling, ↓ cell proliferation within the SM, ↓ synovial fluid | Budras et al. ( | |
| TD 7.5 Gy | 6, 12 Weeks p.i. | |||
| SD 1.0 Gy/SD 5.0 Gy | 3 h p.i. or 4× daily | Zymosan: ↓ joint swelling ↓↓ cartilage/bone destruction Mtb: ↓↓ joint swelling (4× 1 Gy), ↑↑ bone destruction (1× 5 Gy) | Trott et al. ( | |
| TD 4.0 Gy/TD 5.0 Gy | ||||
| SD 1.0 Gy | 24 h p.i. | ↓↓ Joint diameter, ↓ SM-thickness and cell layers, ↓ distance between vessels and SM | Fischer et al. ( | |
| TD 5.0 Gy | 5× Daily | |||
| SD 1.0 Gy/TD 5 Gy | Day 15 p.i. | ↓↓ HPV, ↓↓ AS, ↓ ESR ↓↓ cartilage- and bone destruction, ↓ iNOS expression, ≈inflammatory infiltration | Hildebrandt et al. ( | |
| SD 0.5 Gy/TD 2.5 Gy | 5× daily | |||
| SD 0.5 Gy/SD 1.0 Gy | Days 10, 15, or 22 p.i | ↓ HPV, ↓ AS, early IR (acute, day 10), and 0.5 Gy most effective. IR (chronic days 22–26) ≈ clinical signs | Liebmann et al. ( | |
| TD 2.5/TD 5.0 Gy | 1× SD/ 5 days (FS1) | |||
| 5× SD/9 days (FS2) | ||||
| SD 0.5/1.0/2.0/5.0 Gy | 6 h after challenge | ≈Inflammatory exudates and cell number ↓ iNOS expression, ↓ IL-1β ↑ Hsp70, ↑ HO-1 | Schaue et al. ( | |
| SD 0.1/0.3/0.6 Gy | 1 h before LPS challenge | ↓ Leucocyte adhesion in intestinal venules (max. 0.3 Gy), ↑ circulating levels of TGF-β1 | Arenas et al. ( | |
| SD 0.5 Gy | 24 h before induction and 4× week | ↓ Weight of spleen, ↓ CD(+)CD4(+)CD8(−) B220(+) Tcells, ↑ FoxP3 T(reg) in spleen, ↓ anti-DNA antibodies | Tago et al. ( | |
| TD 2.5 Gy | ||||
| SD 0.5 Gy | 24 h before RA induction and 4× week | ↓ Clinical symptoms, ↓ joint collapse, cytokines TNF-α, IFN-γ, IL-6 in serum | Nakatsukasa et al. ( | |
| TD 2.5 Gy | ||||
| SD 0.5 Gy | 24 h before EAE induction and 4× week | ↓EAE incidence, ↓clinical score, ↓ TNF-a, IL-6, IL-17 in spleen, ↑ FoxP3 T(reg) in spleen, ↓ IFN-γ in serum | Tsukimoto et al. ( | |
| TD 2.5 Gy | ||||
| SD 0.5 Gy | 6–7 weeks and 10–12 weeks | ↓↓ Ankle swelling, ↑grip strength at the beginning PA | Frey et al. ( | |
| TD 2.5 Gy | ||||
| SD 0.5 Gy | 24 h before RA induction and 4× week | ↓ Arthritis score, ↓ antitype II collagen ab, ↑ FoxP3(+) T(reg) in spleen, ↓ IL-6, IL-17 | Nakatsukasa et al. ( | |
| TD 2.5 Gy | ||||
| SD 0.4 Gy | 24 h before or at day 25 | ↓ AS, ↓ number of lymphocytes in circulation, ↑ FoxP3 T(reg) in circulation | Weng et al. ( | |
A, animal; AS, arthritis score; EAE, experimental autoimmune encephalomyelitis; ESR, erythrocyte sedimentation rate; HO-1, heme oxygenase; HPV, hind paw volume; hTNFtg, human TNF transgenic mice; Hsp70, heat shock protein70; IL-1, Interleukin-1; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; M, experimental model; Mtb, mycobacterium tuberculosis; IR, ionizing radiation; OA, osteoarthritis; RA, rheumatoid arthritis; SD, single dose; SM, synovial membrane; TD, total dose; TGF-β.
Figure 1Actual model on the modulation of inflammatory cell activity and factors involved in the anti-inflammatory effect of LD-RT (<1 Gy). Irradiation resulted in a hampered adhesion of peripheral blood mononuclear cells (PBMC) to the endothelium, due to the secretion of the anti-inflammatory cytokine transforming growth factor β1 (TGF-β1), a decreased expression of E-selectin on the surfaces of endothelial cells, a local increase of apoptosis, and the proteolytic shedding of L-selectin from PBMC. In stimulated macrophages a diminished activity of the inducible nitric oxide synthase (iNOS) in line with reduced levels of nitric oxide (NO), a lowered production of reactive oxygen species (ROS), and a diminished secretion of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) may contribute to local anti-inflammatory effects. Moreover, polymorphonuclear cells (PMN) respond to low-dose exposure with a locally increased rate of apoptosis, a hampered secretion of CCL20 chemokine and alterations in signal transduction pathways p38 mitogen activated protein kinase (MAPK) and protein kinase B (AKT).